Alligator tears for Teva

From Briefing.com...

"Prudential raises their Teva Pharmaceuticals/TEVA tgt to $50 from $42, as they believe Copaxone and patent settlements help keep TEVA's earnings growth steady. Although they find it difficult to include generic launches in their model until they have a court win or other source of confidence, they feel the increased visibility these settlements provide should be reflected in a higher multiple on near-term earnings. Firm notes that Teva has already announced or executed agreements with GSK on Lamictal, WYE on Effexor/Effexor XR, BMY on Paraplatin and CEPH on Provigil. They believe Teva's portfolio of patent challenges is the largest of the generic companies (especially in combination with IVAX), and say additional settlement announcements are likely."

And yes, I remain long the shares. Since the recommendation of TEVA, the share price has rallied to ~$45 from ~$35, a gain of ~35% in little more than two months. Not too shabby.